NUL
Nul Health Limited (Nul) is a London-based UK telehealth subscription startup that helps adults reduce or quit alcohol via two programmes on its platform: a Sinclair Method medication programme (Naltrexone/Nalmefene from £199/month) and a six-month IFS therapy programme (from £299/month), delivered through CQC-regulated partner Blueco Healthcare.
- Company typePrivate
- Founded2023
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2C
- OfferingServices
What NUL does
Nul Health Limited (Nul) is a London-based, UK-only telehealth subscription startup that helps adults reduce or quit alcohol consumption through two complementary programmes delivered on a single web platform (choosenul.com and app.choosenul.com). The Nul Medication Programme applies The Sinclair Method (TSM), using opioid antagonists Naltrexone or Nalmefene taken one to two hours before drinking to drive pharmacological extinction of the alcohol-reward response, supported by 28-day clinician reviews, weekly coach-led share sessions and at-home Liver Function Tests supplied via Thriva. The Nul IFS Therapy Programme is a medication-free, six-month Internal Family Systems therapy journey combining 1:1 and group therapy with curated audio/video resources, designed for emotionally driven drinkers.
The underlying technology integrates an online eligibility assessment and onboarding workflow, e-prescribing through CQC-registered Blueco Healthcare, GPhC-registered pharmacy dispensing with Royal Mail Tracked 24 & Signed For delivery, and the Thriva LFT pipeline. Nul's go-to-market is direct-to-consumer and product-led: customers self-onboard via the website, complete an online consultation with a Blueco clinician, and receive medication or therapy remotely. Revenue is generated primarily through monthly subscriptions — Medication Programme from £199/month with a 3-month minimum, IFS Therapy Programme from £299/month with a 6-month minimum — supplemented by a non-refundable £50 suitability assessment fee and ancillary fees (£40 replacement LFT, £40 in-clinic LFT, £60 nurse home visit, £129 replacement therapy session). Marketing is content- and PR-led, anchored by sustained UK mainstream press coverage and a self-serve "Check my eligibility" funnel, with no paid acquisition or field sales motion.
NUL firmographics
Firmographics- Name
- NUL
- Legal name
- Nul Health Limited
- Website
- https://choosenul.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Nul Health Limited (Nul) is a London-based UK telehealth subscription startup that helps adults reduce or quit alcohol via two programmes on its platform: a Sinclair Method medication programme (Naltrexone/Nalmefene from £199/month) and a six-month IFS therapy programme (from £299/month), delivered through CQC-regulated partner Blueco Healthcare.
- Ownership category
- akta.pro rank
NUL industry classification
Industry- Product category
- Telehealth alcohol reduction services
- NAICS
- Health Care and Social Assistance (62), Services for the Elderly and Persons with Disabilities (624120)
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- DTC Telehealth with Integrated Online Pharmacy (Cash-Pay/Subscription) (HLALAIAA)
- akta.pro secondary industries
- Non-prescription / OTC Digital Therapeutics (HLACANAC), Smoking Cessation & Nicotine Replacement Therapy (Gum, Patches, Lozenges) (CRADAMAI)
Keywords
Where NUL is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
NUL business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales
Revenue model
- Nul Medication Programme subscription: Monthly recurring subscription from £199/month with a minimum 3-month Initial Term, automatically renewing into rolling 3-month cycles. Includes clinician reviews, on-demand prescription refills, weekly coach-led sessions and at-home LFTs (Thriva). Revenue is recognised monthly with the longer Initial Term providing committed cash flow.
- Nul IFS Therapy Programme subscription: Monthly recurring subscription from £299/month with a 6-month Initial Term, converting to a rolling monthly subscription. Includes 1:1 IFS therapist sessions, group therapy, and tailored video/audio resources. No medication revenue attached.
- One-off Medication suitability assessment fee: Non-refundable £50 one-off initial clinical assessment fee paid before Medication Programme onboarding; immediate service start upon online consultation submission removes statutory cooling-off rights.
- Ancillary fees (LFT kits, in-person testing, missed therapy sessions): Usage/incident-based fees on top of subscriptions: £40 per replacement LFT kit, £60 nurse home-visit or £40 in-clinic LFT appointment, £129 per replacement therapy session. Pure incremental revenue with no recurring component.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Nul Medication Programme — from £199/month with min 3-month commitment plus £50 one-off assessment |
| Subscription | Monthly | Nul IFS Therapy Programme — from £299/month with 6-month commitment |
| One time/ perpetual license | Pay-as-you-go | One-off Medication suitability assessment — £50 non-refundable |
| Usage-based | Pay-as-you-go | Ancillary fees: LFT replacement kits, in-person LFT appointments, replacement therapy sessions |
Go-to-market motion4 records
Distribution channels3 records
Marketing channels7 records
NUL product offering
Product offeringCore offering
Nul operates a direct-to-consumer telehealth subscription platform that delivers two evidence-based alcohol-reduction programmes to UK adults: the Sinclair Method-based Medication Programme (Naltrexone or Nalmefene taken before drinking, with monthly clinician reviews and weekly coaching, from £199/month) and the IFS Therapy Programme (six months of Internal Family Systems therapy without medication, from £299/month). Clinical services, prescribing and pharmacy dispensing are provided by CQC-regulated partner Blueco Healthcare, with discreet Royal Mail home delivery and at-home Thriva liver function tests integrated into the care pathway.
Product overview
Nul operates a single subscription telehealth platform (choosenul.com / app.choosenul.com) under the Nul Health Limited entity, delivering two complementary programme products: the Nul Medication Programme (a Sinclair Method-based pharmacotherapy offering Naltrexone or Nalmefene with clinician check-ins) and the Nul IFS Therapy Programme (a medication-free, six-month Internal Family Systems therapy journey). Both programmes are layered on the same underlying platform, which handles onboarding, eligibility assessment, subscription billing on a fixed monthly cycle, clinician/therapist scheduling, prescription refills and ongoing patient check-ins, with clinical services delivered in partnership with Blueco Healthcare and liver function testing provided via Thriva.
Differentiator
Problem solved
Functional benefit
Brands
- Nul Medication Programme: Subscription medication-based programme based on The Sinclair Method, using Naltrexone or Nalmefene, from £199/month with a minimum 3-month commitment.
- Nul IFS Therapy Programme
Products and services
- Nul Medication Programme A Sinclair Method-based subscription programme offering Naltrexone or Nalmefene opioid-antagonist medication taken 1-2 hours before drinking to drive pharmacological extinction of alcohol-reward behaviour. Includes monthly clinician reviews, Thriva at-home liver function tests, weekly coach-led support sessions and on-demand prescription refills. Targeted at UK adults aged 18+ who want to cut back or quit drinking via a science-based, non-abstinence-first pathway.
- Nul IFS Therapy Programme A six-month, medication-free alcohol reduction programme based on Internal Family Systems (IFS) therapy, combining 1:1 sessions with an experienced IFS therapist, group therapy, and a tailored audio/video resource library. Designed for UK adults whose drinking is driven by stress or emotional factors and who prefer a therapy-led path over pharmacotherapy.
- Nul Telehealth Platform (choosenul.com / app.choosenul.com) The underlying subscription telehealth platform operated by Nul Health Limited that delivers both the Medication and IFS Therapy programmes. Provides online eligibility screening, clinician/therapist booking, monthly clinical check-ins, prescription management, monthly billing on a fixed cycle, and access to educational content, support resources and weekly share sessions for UK adult consumers.
Quantifiable outcome
- Sinclair Method reports a 78% success rate in reducing alcohol use long-term (Sinclair, 2001), cited across Nul programmes.
- +2 more outcomes
Companies that use NUL
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
NUL technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature6 records
NUL partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered flagship clinical & pharmacy partner, core diagnostic partner and core clinical research partner.
- Blueco Healthcare Limitedflagship clinical & pharmacy partnerCQC-registered healthcare partner (provider ID 1-19176166626) delivering all online clinic services for Nul, including prescribing, dispensing, and delivery via its GPhC-registered pharmacy (9013068) at 468 Ranglet Road, Walton Summit, Preston. Haroon Amanji is Superintendent Pharmacist and CQC Registered Manager. Operationally, Blueco's clinicians access patient SCRs, conduct clinical reviews every 28 days and notify GPs by default — making it the regulated backbone of the Medication Programme.
- Thrivacore diagnostic partnerProvides at-home Liver Function Test (LFT) kits and lab analysis for Nul customers. LFTs are required before the second prescription and used to monitor liver health throughout the Medication Programme.
- NHS Manchester University NHS Foundation Trustcore clinical research partnerCollaborating with Nul on clinical trials of the telehealth alcohol-reduction platform, lending NHS clinical infrastructure and patient cohorts to validate the approach.
- King's College Londoncore clinical research partnerAcademic research partner working with Nul on clinical trials for the alcohol-reduction platform, contributing research expertise and clinical-trial methodology.
- Manchester Metropolitan Universitycore clinical research partnerAcademic research partner collaborating with Nul on clinical trials of its alcohol-reduction platform, contributing research expertise.
Scale indicators8 records
Recent moves8 records
Expansion highlights6 records
NUL competitors and assessment
Company assessmentDirect peers
- Monument: US-headquartered digital alcohol treatment platform offering telehealth clinician visits, medication (including naltrexone), therapy and community support. Closest direct competitor to Nul's combined medication-plus-therapy subscription model.
- Eleanor Health: Telehealth and in-person addiction treatment provider combining medication-assisted treatment, therapy and peer support for alcohol and opioid use disorder. Comparable integrated care model.
- Ria Health: US telehealth programme for alcohol use disorder combining naltrexone/Sinclair Method medication, remote coaching and digital tools. Direct comparable on Nul's pharmacotherapy-plus-coaching architecture.
- Confidant Health: Digital addiction care platform combining telehealth clinician visits, medication management (including naltrexone) and in-app coaching. Comparable on integrated medication-plus-coaching model.
- Pelago: Digital substance-use treatment platform (formerly Quit Genius) serving employers and health plans with clinician-led telehealth for alcohol, tobacco and opioid use. Closest large-scale direct competitor in digital alcohol treatment.
- Workit Health: Telehealth addiction treatment provider offering medication-assisted treatment (including naltrexone) for alcohol and opioid use disorder, with online therapy and coaching. Direct comparable business model and regulatory profile.
- Lionrock: Online alcohol and drug treatment provider delivering telehealth counselling, group sessions and clinician support. Direct competitor in the digital alcohol-treatment category.
Regional players
- Zava: UK and European direct-to-consumer telehealth platform offering online consultations and prescriptions across multiple conditions. Regional peer for UK DTC telehealth infrastructure and clinical workflow.
Emerging players
- Oar Health: Direct-to-consumer telehealth service for naltrexone prescribing to reduce alcohol cravings. Emerging player focused specifically on pharmacotherapy, with narrower scope than Nul's combined offering.
Broad incumbents
- Babylon Health: UK-headquartered broad telehealth and digital primary-care provider offering online consultations, prescriptions and digital health tools. Broader incumbent operating in UK DTC telehealth with overlapping delivery model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
NUL social profiles
Digital presenceNUL compliance and trust
Trust signalCompliance4 records
NUL financial estimates
Financial estimateRevenue estimate
Valuation estimate
NUL leadership team
Management profileNumber of profiles
Profiles7 records
NUL subsidiaries and ownership
Company hierarchySubsidiaries1 record
NUL funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NUL M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NUL
What does NUL do?
Nul operates a direct-to-consumer telehealth subscription platform that delivers two evidence-based alcohol-reduction programmes to UK adults: the Sinclair Method-based Medication Programme (Naltrexone or Nalmefene taken before drinking, with monthly clinician reviews and weekly coaching, from £199/month) and the IFS Therapy Programme (six months of Internal Family Systems therapy without medication, from £299/month). Clinical services, prescribing and pharmacy dispensing are provided by CQC-regulated partner Blueco Healthcare, with discreet Royal Mail home delivery and at-home Thriva liver function tests integrated into the care pathway.
Is NUL a public or private company?
NUL is a private company. It is classified as venture growth investor backed and is currently operating.
When was NUL founded?
NUL was founded in 2023. It employs 11 to 50 people.
Where is NUL based?
NUL is headquartered in London, United Kingdom, in the Europe region.
How does NUL make money?
Four revenue lines are on record. Nul Medication Programme subscription is the primary driver. The others are nul IFS Therapy Programme subscription, one-off Medication suitability assessment fee and ancillary fees (LFT kits, in-person testing, missed therapy sessions).
Who are NUL's main competitors?
Direct peers on record are Monument, Eleanor Health, Ria Health, Confidant Health, Pelago, Workit Health and Lionrock. Zava is listed as a regional player. Oar Health is listed as an emerging player. Babylon Health is listed as a broad incumbent.
Does NUL have an API?
No public API is recorded for NUL.
What industry is NUL in?
NUL's product category is Telehealth alcohol reduction services. Its primary akta.pro industry code is HLALAIAA, DTC Telehealth with Integrated Online Pharmacy (Cash-Pay/Subscription), with a secondary code of HLACANAC, Non-prescription / OTC Digital Therapeutics. Its NAICS code is 62 and its SIC code is 8000.